NuVasive‘s COO Keith Valentine sold 6,970 shares of the company’s stock this past Wednesday, according to a report from The Legacy. He sold the shares at an average price of $46.96 for a total transaction value of around $327,311. A few days earlier, Canaccord Genuity set a price target on NuVasive at $51, according to a WKRB News & Analysis report.
K2M received an average broker rating score of 1.00 — a Strong Buy — from four brokers that cover the stock, according to Zacks Investment Research as reported in Ticker Report. The brokers set a 12-month consensus price of $21.
Globus Medical received a stock price of $28 from Canaccord Genuity, according to a Sleek Monkey report.
Amedica short interest shares shot up by 195 percent or 224,538 shares, according to a Rock Hill Daily report.
LDR President and CEO Christophe Lavigne sold 25,000 shares at $33.46 on Jan. 15 for a total value of $836,500, according to a report from Candle Strips.
More articles on orthopedic devices:
Zimmer, Medtronic, Stryker & more—13 key notes
5 things to know about the SpineGuard “smart screw” European patent
Stryker earnings drop 48.4% in 2014…but is an acquisition looming? 12 key points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
